Is Dose Adjustment Based on Several Factors of Body Size Descriptors Effective for Prevention of Thrombocytopenia by Linezolid Therapy in Hemodialysis Patients?

Previous study suggested that low body weight was one of the risk factors of thrombocytopenia induced by linezolid in non-hemodialysis patients. However, there have been little investigations for the linezolid-induced thrombocytopenia in hemodialysis patients. This study was to evaluate the association between several factors of body size descriptors and thrombocytopenia in hemodialysis-patients. No factor of body size descriptors showed significant correlation with linezolid-induced thrombocytopenia (patients with thrombocytopenia vs patients without thrombocytopenia: body weight; 60.0 kg vs 55.3 kg, p = 0.82: body mass indices; 21.1 kg/m2 vs 21.2 mg/m2, p = 0.44: ideal body weight; 61.2 kg vs 59.5 kg, p = 0.21: lean body weight; 50.1 kg vs 45.7 kg, p = 0.64: dosage amount; 20.0 mg/kg vs 21.7 mg/kg, p = 0.74: body surface area; 1.65 m2 vs 1.54 m2, p = 0.43). There were not significant differences in the body size descriptors between linezolid therapy for more than 14 days and for less than 13 days (more than 14 days vs less than 13 days: body weight; 53.5 kg vs 56.8 kg, p = 0.75: body mass indices; 20.9 kg/m2 vs 21.1 mg/m2, p = 0.47: ideal body weight; 60.3 kg vs 59.9 kg, p = 0.17: lean body weight; 44.3 kg vs 47.7 kg, p = 0.56: dosage amount; 22.4 mg/kg vs 21.1 mg/kg, p = 0.67: body surface area; 1.51 m2 vs 1.59 m2, p = 0.37). Our data suggested that dosage adjustment of linezolid based on body weight was not recommended in hemodialysis-patients.